Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced progress in its pipeline targeting cancer-related pain and neuropathy, according to a shareholder letter from CEO Greg Duncan. In 2025, the company recruited over 100 patients for the Halneuron Phase 2b Chemotherapy Induced Pain (HALT-CINP) Study, enabling an interim analysis to determine final study sample size and optimal analysis methodology. The company also secured a royalty-free, global license for SP16 IV, a potential treatment for neuropathy and inflammation caused by cancer chemotherapy, with its Phase 1b study fully funded by a development grant from the National Cancer Institute. Additionally, Dogwood Therapeutics advanced a synthesized version of Halneuron for Phase 3 development, aiming to reduce manufacturing costs and improve yields, and filed for new intellectual property protection that could extend Halneuron’s protection to 2046. Key 2026 goals include releasing final Phase 2b data for Halneuron in Q3 2026 and submitting end of Phase 2 summary, manufacturing, and Phase 3 development plans to the FDA, contingent on favorable Phase 2b outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-004838), on January 20, 2026, and is solely responsible for the information contained therein.